Boxed warning: Foundayo (orforglipron), Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg) all carry an FDA boxed warning for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). All three are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) (FDA Rybelsus/semaglutide labeling, dailymed.nlm.nih.gov; FDA Wegovy prescribing information).
Key Takeaways
- All three FDA-approved oral GLP-1s share a class-wide boxed warning contraindicating their use in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome.
- A history of pancreatitis and severe gastrointestinal conditions — particularly severe gastroparesis — are important safety considerations across the class; Rybelsus’s FDA label specifically states it “is not recommended in patients with severe gastroparesis.”
- Pregnancy and breastfeeding are not recommended with any of these medications; discuss family planning with your prescriber before starting treatment.
- Foundayo has specific interaction considerations involving CYP3A4 pathways and a documented need to evaluate oral contraceptive efficacy during titration.
- This article is an educational overview, not a substitute for a full medical evaluation — only a healthcare provider can determine whether an oral GLP-1 is appropriate for you based on your complete medical history.
The Class-Wide Boxed Warning: Thyroid C-Cell Tumors (MTC/MEN 2)
The single most prominent safety warning across Foundayo, Wegovy pill, and Rybelsus is the FDA boxed warning for thyroid C-cell tumor risk. This warning stems from rodent studies showing that semaglutide (the active ingredient in Wegovy pill and Rybelsus) “causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures” in mice and rats (FDA labeling via dailymed.nlm.nih.gov). It is currently unknown whether these drugs cause thyroid C-cell tumors, including MTC, in humans, since the human relevance of the rodent finding has not been determined.
Despite this uncertainty, the FDA requires — as a precaution — that these drugs be contraindicated in:
- Patients with a personal history of medullary thyroid carcinoma (MTC)
- Patients with a family history of MTC
- Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Watch for possible symptoms of thyroid tumors, including a lump or swelling in the neck, hoarseness, difficulty swallowing, or shortness of breath, and report any of these to a healthcare provider immediately, as noted in Foundayo’s FDA-referenced approval materials (PR Newswire).
Pancreatitis History
Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists, including Rybelsus, per its FDA label (FDA Rybelsus prescribing information). If you have a history of pancreatitis, this is an important factor to discuss with your prescriber before starting any GLP-1 medication, oral or injectable. Treatment should be discontinued promptly if pancreatitis is suspected, and patients should be observed carefully for signs and symptoms — particularly persistent, severe abdominal pain, sometimes radiating to the back.
Severe Gastroparesis
Rybelsus’s FDA prescribing information explicitly states that the drug “is not recommended in patients with severe gastroparesis,” reflecting the fact that all GLP-1 receptor agonists slow gastric emptying — a mechanism that compounds an already-impaired condition in patients with severe gastroparesis (FDA Rybelsus labeling). The FDA has also flagged severe gastrointestinal adverse reactions, “sometimes severe,” as a specific warning and precaution for Rybelsus. Similar gastric-emptying-related caution applies broadly across the GLP-1 class, including Foundayo and Wegovy pill, even where it is not spelled out with the same specific wording.
Pregnancy and Breastfeeding
None of the three approved oral GLP-1s are recommended during pregnancy or breastfeeding. The FDA’s approval letter for Foundayo specifically noted that current data are insufficient to assess “exposure to orforglipron in pregnancy,” and the agency has required additional studies on this question as part of Foundayo’s post-marketing requirements (FDA approval letter, accessdata.fda.gov). If you are pregnant, planning a pregnancy, or breastfeeding, discuss alternative approaches with your healthcare provider rather than starting or continuing an oral GLP-1 without medical guidance.
Foundayo-Specific Interaction: Oral Contraceptives
Foundayo’s FDA-referenced labeling notes a specific consideration for patients using oral contraceptives: because Foundayo can affect gastric emptying and potentially drug absorption during titration, contraceptive efficacy may be reduced during the dose-escalation period. Patients using oral contraceptives should discuss this with their prescriber, who may recommend a backup contraceptive method during titration or an alternative form of birth control (see the SHARED_SPEC safety signals summary for the underlying reference). This is a decision for you and your prescriber, not something to manage independently.
Our Top 3 · July 2026
The best GLP-1 providers right now
Independently reviewed. Ranked by price, medication access, provider quality, and patient outcomes.
Renew GLP
Personalized GLP-1, GIP plans: Semaglutide & Tirzepatide.
Medvi
No membership or hidden fees. Everything you need is included.
Trimi
US-licensed clinicians and shipped to your door, from $99/mo.
CYP3A4 Drug Interactions (Foundayo)
Foundayo’s labeling also flags potential interactions involving the CYP3A4 metabolic pathway. Depending on what other medications you take — particularly strong CYP3A4 inducers or drugs that are CYP3A4 substrates — dose adjustments may be necessary. This is another reason a full medication review with your prescriber or pharmacist is an essential step before starting Foundayo, not an optional one.
Other Class-Wide Warnings
Beyond the boxed warning, FDA labeling for semaglutide-based orals (Wegovy pill, Rybelsus) and Foundayo references several additional precautions relevant to who should approach these drugs with particular caution:
- Gallbladder disease: Increased occurrence of cholelithiasis (gallstones) and cholecystitis has been observed with semaglutide treatment (FDA Wegovy prescribing information).
- Hypoglycemia: Risk increases when combined with insulin or sulfonylureas, particularly relevant for patients with type 2 diabetes.
- Acute kidney injury: Can result from dehydration linked to GI side effects like vomiting and diarrhea.
- Diabetic retinopathy complications: Has been reported in trials with semaglutide, particularly relevant for patients with type 2 diabetes and existing retinopathy.
- Hypersensitivity reactions: Anaphylaxis and angioedema have been reported postmarketing with semaglutide products; discontinue and seek medical help immediately if suspected.
- Suicidal behavior or thinking: Included as a monitoring consideration in some GLP-1 labeling; report any new or worsening mood changes to your healthcare provider.
Per-Drug Contraindication Summary
| Drug | Key Contraindications/Cautions |
|---|---|
| Foundayo (orforglipron) | Personal/family history of MTC or MEN 2; not established safe in pregnancy or pediatric patients; caution with CYP3A4-interacting drugs; monitor oral contraceptive efficacy during titration; use with other GLP-1 receptor agonists not recommended |
| Wegovy pill (oral semaglutide 25 mg) | Personal/family history of MTC or MEN 2; history of severe hypersensitivity to semaglutide; caution with pancreatitis history, gallbladder disease, diabetic retinopathy |
| Rybelsus (oral semaglutide 3/7/14 mg) | Personal/family history of MTC or MEN 2; not recommended in severe gastroparesis; caution with pancreatitis history; T2D-only FDA label (weight-loss use is off-label) |
For dosing-specific information relevant to each drug, see the WeightLossInjections.com Rybelsus dosing guide and the WeightLossInjections.com Foundayo dosing guide.
Drug-Drug Interactions Worth Flagging for Your Prescriber
Beyond the contraindications above, a full medication review matters because GLP-1 receptor agonists can interact with other drugs in ways that aren’t always obvious:
- Insulin and sulfonylureas: Combining these with any GLP-1 receptor agonist increases hypoglycemia risk, requiring closer blood sugar monitoring and possible dose adjustments to the other medications.
- Other oral medications generally (Wegovy pill, Rybelsus): Because these drugs delay gastric emptying, they can affect how quickly other oral medications are absorbed. This is part of why the strict fasting and 30-minute waiting period exists — it’s designed to minimize interference with both the GLP-1 drug’s own absorption and that of other medications taken afterward.
- CYP3A4-interacting drugs (Foundayo): Certain inducers or substrates of the CYP3A4 metabolic pathway may require Foundayo dose adjustments; your prescriber and pharmacist should review your full medication list, including over-the-counter drugs and supplements.
- Other GLP-1 receptor agonists: Combining Foundayo, Wegovy pill, or Rybelsus with another GLP-1 receptor agonist (including injectables like Ozempic, Wegovy, Mounjaro, or Zepbound) is not recommended, since this does not improve outcomes and may increase side effect risk without established safety data supporting the combination.
Why Full Medical History Disclosure Matters
Because the contraindications and warnings across these three drugs touch multiple organ systems — thyroid, pancreas, gallbladder, kidneys, eyes (in patients with diabetes), and potentially the liver in Foundayo’s case — a thorough intake conversation with your prescriber is not a formality. Conditions you might not think to mention, such as a distant family member’s thyroid cancer diagnosis, a past episode of pancreatitis you attributed to another cause, or an existing eye condition unrelated to diabetes, can all be relevant to whether and how an oral GLP-1 should be prescribed and monitored for you specifically. If you’re unsure whether something in your history is relevant, the safest approach is to mention it anyway and let your healthcare provider determine its significance.
This Is Not a Complete List
FDA prescribing information for each drug contains the full, legally binding list of contraindications, warnings, and precautions. This article summarizes major, high-relevance points but is not exhaustive. Always review the complete prescribing information for your specific medication, and disclose your full medical history — including thyroid conditions, pancreatitis, GI conditions, kidney or liver disease, pregnancy status, and all current medications — to your healthcare provider before starting treatment.
Frequently Asked Questions
Who should never take Foundayo, Wegovy pill, or Rybelsus?
Anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2 syndrome should not take any of these drugs, per the class-wide FDA boxed warning. Beyond that, individual contraindications vary by drug and by personal medical history — a healthcare provider needs to evaluate your specific situation.
Can I take an oral GLP-1 if I have a history of pancreatitis?
This requires a careful conversation with your prescriber. Acute pancreatitis has been observed with GLP-1 receptor agonists, including Rybelsus, per FDA labeling, so your prescriber will need to weigh your history carefully before recommending treatment.
Is it safe to take Rybelsus if I have gastroparesis?
Rybelsus’s FDA label specifically states it is not recommended in patients with severe gastroparesis. Discuss your specific GI history with your prescriber, who may recommend a different approach.
Does Foundayo interact with birth control pills?
Foundayo’s labeling notes that contraceptive efficacy may be affected during titration due to effects on gastric emptying and absorption. Talk to your prescriber about backup contraception or alternative methods if you use oral contraceptives.
Can pregnant or breastfeeding women take oral GLP-1s?
These medications are not recommended during pregnancy or breastfeeding, and safety data in these populations remains limited — the FDA has required additional studies specifically addressing pregnancy exposure for Foundayo. Speak with your healthcare provider about alternative approaches if you are pregnant, trying to conceive, or breastfeeding.
Medical disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Foundayo (orforglipron), Wegovy pill (oral semaglutide 25 mg), and Rybelsus (oral semaglutide 3/7/14 mg) are prescription medications with important safety information and contraindications. Discuss any medication decision with a qualified healthcare provider. Content published by WeightLossInjections.com, your complete resource for GLP-1 medications — injections and pills alike.
Sources:
